Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Rheumatoid arthritis (RA) has a multifactorial aetiopathogenesis with both genetic and environmental factors implicated, giving rise to immune dysregulation with resultant joint inflammation and tissue damage. The emergence of biologic and small molecular targeted therapeutics has validated the role of many key molecules and cells in the pathogenesis of RA. In this article we update our previous review, adding any new developments within the last couple of years with regards to the major contributors to RA pathogenesis, including genetics, cellular components, cytokines and new potential signalling mechanisms and targets. Moreover, we update on any further evidence of the role of the microbiome in RA, and also new emerging concepts and challenges in RA therapy.

More information Original publication

DOI

10.1016/j.mpmed.2021.12.001

Type

Journal article

Publisher

Elsevier

Publication Date

2022-01-25T00:00:00+00:00

Volume

50

Pages

133 - 137

Total pages

4